查詢結果分析
來源資料
相關文獻
- Transformation of Non-Small Cell Lung Cancer to Combined Squamous Cell and Small Cell Carcinoma after Chemotherapy: Case Report
- A Study of Some COLOR Compound Words in English (Part 1)
- 影響組織內部勞動市場因素之研究--以國內2000大製造業為例
- 生長調節劑對不同生育期的薜荔插穗發根之影響
- 臺灣經濟發展中社會面貌的變化
- 非小細胞肺癌術前輔助性化學治療的經驗
- 反轉變體症候群: 一例報告
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
- 以病人為中心的護理--帕西護理實務法
- A Study of Some COLOR Compound Words in English(Ⅱ)
頁籤選單縮合
題 名 | Transformation of Non-Small Cell Lung Cancer to Combined Squamous Cell and Small Cell Carcinoma after Chemotherapy: Case Report=非小細胞肺癌經化學治療後轉變為聯合型鱗狀上皮細胞與小細胞癌:病例報告 |
---|---|
作 者 | 羅永鴻; 陳育民; | 書刊名 | 胸腔醫學 |
卷 期 | 27:5 2012.10[民101.10] |
頁 次 | 頁305-310 |
分類號 | 415.468 |
關鍵詞 | 聯合型鱗狀上皮細胞與小細胞癌; 非小細胞肺癌; 轉變; Combined squamous cell and small cell carcinoma; Non-small cell lung cancer; Transformation; |
語 文 | 英文(English) |
中文摘要 | 大約百分之五的小細胞肺癌會同時具有非小細胞癌的成分。據估計聯合型小細胞肺癌與鱗狀上皮細胞癌或腺癌的發生率約占所有小細胞肺癌的百分之一至二以下。我們報告一例非小細胞肺癌經化學治療後轉變為聯合型鱗狀上皮細胞與小細胞癌。小細胞肺癌幾乎只發生在吸菸的人身上。據我們所知,這是第二個被報導的發生在不抽菸患者身上的聯合型鱗狀上皮細胞與小細胞癌。肺癌經治療後發生組織學形態上的變化被認為是不常見的狀況。腫瘤的異質性可能在最初的診斷時就發現,也可能隨著時間的推移而自然發生,或者是被化學治療或放射線治療而誘發。這種現象更加強調了在組織學、及分子檢驗方面,例如上皮生長因子受體基因突變狀態方面作確定診斷的重要性,如此才能對肺癌的治療作出完善之計畫。 |
英文摘要 | About 5% of small-cell lung cancer (SCLC) may be combined with non-small cell components. The estimated incidence of SCLC combined with squamous cell and/or adenocarcinoma was probably less than 1% to 2% of all SCLC cases. We presented a case with transformation of non-small cell lung cancer to combined squamous cell and small cell carcinoma after chemotherapy. SCLC occurs almost exclusively in smokers. To our knowledge, this is the 2nd reported case of combined small and squamous cell carcinoma occurring in a patient without a smoking history. A histological change in lung cancer after treatment is considered unusual. Tumor heterogeneity may be found at initial diagnosis, may occur spontaneously over time or may be elicited by chemotherapy and/or radiotherapy. This emphasizes the importance of histological confirmation, even at molecular levels, such as epidermal growth factor receptor (EGFR) mutation status, in order to make appropriate plans for lung cancer therapy. |
本系統中英文摘要資訊取自各篇刊載內容。